Contract processing services of medical cannabis flower to extracted products for licensed producers.
Supply of full-spectrum medical cannabis oil. Products can be marketed under the customer’s own brand.
From our facility in Denmark, we manufacture full-spectrum cannabis oil for declaration of THC, CBD, and balanced formulations. Our unique manufacturing capabilities enable us to create the highest quality of products with a well-preserved profile of terpenes and flavonoids. Valcon Medical is GMP certified.
Standardised Cannabis Oil
- Full-spectrum C02–extracted
- THC, CBD, mixed, or balanced
- MCT carrier oil
- 30 ml primary packaging
Products are manufactured under EU-GMP and tested in accordance with the German Monograph for cannabis extracts, DAB Eingestellter Cannabisextract, and the European Pharmacopoeia, Ph. Eur. Products are composed of a specified amount of extracted cannabinoids from Cannabis Sativa L. flowers (floss) of a defined strain, in MCT oil (medium-chain triglycerides). The extraction solvent is carbon dioxide.
Bulk Herbal Cannabis Extract
- Full-spectrum C0₂–extracted
- THC, CBD, or Balanced
- 50-500 ml container
Cannabis herbal extracts are manufactured under EU-GMP and tested in accordance with the German Monograph for cannabis extracts, DAB Eingestellter Cannabisextract (up to standardization), and the European Pharmacopoeia, Ph. Eur. Products are composed of a > 70% concentrated soft extract of cannabinoids from Cannabis Sativa L. flowers (floss) of a defined strain. The extraction solvent is carbon dioxide.
EU-GMP Certified Contract Manufacturer of Medical Cannabis Extracts
Valcon Medical is a European manufacturing organisation specialising in medical cannabis extracts. We offer a complete outsourcing solution by covering every phase, from product development to end-product manufacturing.About us
The European Pharmacopoeia Commission (EPC) has adopted a new European monograph for Cannabis flower
The European Pharmacopoeia Commission has adopted a new European monograph for Cannabis flower at the latest Commission meeting in June 2023. The monograph describes quality requirements for the raw material Cannabis flower.
Valcon Medical has reached another significant milestone with the successful implementation of a consistent supply chain to United Kingdom
In United Kingdom Medicinal Cannabis is classified as an unlicensed medicine/Specials and manufactured to meet a specific patient’s clinical needs. Valcon Medical offers exciting partnership opportunities for standardised cannabis oil brands in the United Kingdom.
Valcon Medical is proud to announce its new partnership agreement with a well reputed Polish manufacturer of medicinal cannabis
Introduction of medicinal cannabis to the Polish market requires a marketing authorisation for a pharmaceutical raw material to prepare prescription drugs in the form of non-fibrous hemp herbs, extracts, and tinctures.
Valcon Medical acquires Danish cannabis distributor and re-packer ScanLeaf ApS, extends product reach and capabilities
ScanLeaf’s market penetration, along with additional licensing, further strengthens Valcon’s position in the European Medical Cannabis market. Valcon Medical are excited to announce that they have completed the acquisition of Scanleaf ApS.
Valcon Medical Announces First Dispatch of EU-Certified Medical Cannabis Extracts and Standardised Oils to Germany
The first dispatch of EU-certified medical cannabis extracts and standardised oils to Germany highlights Valcon Medical's poised to significantly impact the medical cannabis industry and the lives of chronic patients.
ENEXIS makes an investment in Denmark-based medical cannabis group Valcon Medical
Valcon Medical Closes Series C Round and Launches Global Commercial Sales of Medical Cannabis Products - Funding led by Altitude Investment Management, Artemis Growth Partners, and Enexis AB, increases total capital raised to €11.8 million.
Hasse Skovbo Knap is a scientific specialist in the company Valcon Medical – talent 100 Berlingske
Hasse Skovbo Knap is a scientific specialist at Valcon Medical, which was established due to the medicinal cannabis pilot programme that came into force in 2018. The company aims to extract oil from cannabis flowers grown in Denmark.
Valcon Medical Granted Authorisation by The Danish Medicines Agency to Manufacture Cannabis Intermediate products for Danish Pilot Programme
Valcon Medical has a build a state-of-the-art manufacturing facility and rigorous quality control processes ensure the production of pharmaceutical-grade cannabis intermediate products, meeting the strict regulatory requirements set by The Danish Medicines Agency.
Valcon Medical Granted Authorisation by The Danish Medicines Agency for Manufacturing Cannabis Bulk Extracts under the Pilot Programme
With the authorisation to manufacture cannabis bulk extracts under the pilot programme, the company will leverage its expertise to manufacture high-quality cannabis bulk extracts, ensuring strict adherence to regulations and guidelines.
Valcon Medical granted authorisation by The Danish Medicines Agency for activities with euphoriant substances
Danish Medicines Agency has granted Valcon Medical the necessary approval to engage in activities related to euphoriant substances marking a significant milestone for and enforces its commitment to providing safe and effective treatments to chronic patients.